Small molecules in oncology:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Berlin [u.a.]
Springer
2010
|
| Schriftenreihe: | Recent results in cancer research
184 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XVI, 238 S. Ill., graph. Darst. |
| ISBN: | 9783642012211 9783642012228 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV035862003 | ||
| 003 | DE-604 | ||
| 005 | 20091217 | ||
| 007 | t | ||
| 008 | 091204s2010 gw ad|| |||| 00||| eng d | ||
| 020 | |a 9783642012211 |9 978-3-642-01221-1 | ||
| 020 | |a 9783642012228 |9 978-3-642-01222-8 | ||
| 035 | |a (OCoLC)495596327 | ||
| 035 | |a (DE-599)BVBBV035862003 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BE | ||
| 049 | |a DE-29 |a DE-19 |a DE-12 | ||
| 050 | 0 | |a RC261 | |
| 082 | 0 | |a 616.994061 |2 22 | |
| 084 | |a XI 7000 |0 (DE-625)153024:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Small molecules in oncology |c Uwe M. Martens (ed.) |
| 264 | 1 | |a Berlin [u.a.] |b Springer |c 2010 | |
| 300 | |a XVI, 238 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Recent results in cancer research |v 184 | |
| 650 | 4 | |a Antineoplastic Agents |x therapeutic use | |
| 650 | 4 | |a Antineoplastic agents | |
| 650 | 4 | |a Azacitidine |x therapeutic use | |
| 650 | 4 | |a Cancer |x Molecular aspects | |
| 650 | 4 | |a Cancer |x Treatment | |
| 650 | 4 | |a Neoplasms |x drug therapy | |
| 650 | 4 | |a Protein Kinase Inhibitors |x therapeutic use | |
| 650 | 0 | 7 | |a Cytostatikum |0 (DE-588)4068347-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Kleines Molekül |0 (DE-588)4164124-3 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 0 | 1 | |a Kleines Molekül |0 (DE-588)4164124-3 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Martens, Uwe Marc |d 1966- |e Sonstige |0 (DE-588)132250608 |4 oth | |
| 830 | 0 | |a Recent results in cancer research |v 184 |w (DE-604)BV000000043 |9 184 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018719832&sequence=000004&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-018719832 | ||
Datensatz im Suchindex
| _version_ | 1804140841679192064 |
|---|---|
| adam_text | Titel: Small molecules in oncology
Autor: Martens, Uwe Marc
Jahr: 2010
Part I Protein Kinase Inhibitors
1 Imatinib Mesylate 3
Cornelius F. Waller
1.1 Introduction 3
1.2 Chemical Structure 5
1.3 Clinical Pharmacology 6
1.4 Drug Targets 6
1.5 Preclinical Studies 6
1.6 Clinical Data in CML 8
1.6.1 Phase I Trials 8
1.6.2 Phase II Studies 8
1.6.3 Phase III Study (IRIS-Trial) 9
1.6.4 Side Effects/Toxicity 10
1.7 Disease Progression and Imatinib Resistance 11
1.8 Treatment Recommendations for the Use of Imatinib
in Chronic Phase CML 14
1.9 Imatinib in Combination with Other Drugs 15
1.10 Imatinib - Other Targets 15
1.11 Conclusion and Future Perspectives 16
References 17
2 Erlotinib 21
M. Steins, M. Thomas, and M. GeiBler
2.1 Introduction 21
2.2 Mechanism of Action 22
2.3 Non-Small Cell Lung Cancer 22
2.4 Pancreatic Adenocarcinoma 24
2.5 Hepatocellular Carcinoma 27
2.6 Other Tumour Entities 28
References 28
y
vj Contents
3 Axitinib (AG-013736) 33
Ronan Joseph Kelly and Olivier Rixe
3.1 Introduction 33
3.2 Structure of Molecule 34
3.3 Preclinical Data 34
3.3.1 Bioavailability in Humans 36
3.4 Phase II Studies 36
3.4.1 Axitinib in Renal Cell Carcinoma 36
3.4.2 Axitinib in Pancreatic Cancer 37
3.4.3 Axitinib in Metastatic Breast Cancer 38
3.4.4 Axitinib in Thyroid Cancer 38
3.4.5 Axitinib in Other Solid Tumors 39
3.5 Phase III Studies 39
3.6 Toxicity 40
3.7 Drug Interactions 41
3.8 Future 42
References 42
4 Lapatinib 45
Tanja Schneider-Merck and Martin Trepel
4.1 Introduction 45
4.1.1 The Epidermal Growth Factor Receptor Family
of Tyrosine Kinases 45
4.1.2 Human Epidermal Growth Factor Receptors
and Breast Cancer 47
4.2 Structure and Mechanism of Action 47
4.3 Clinical Data 49
4.3.1 Pharmacology 49
4.3.2 Results from Clinical Trials 49
4.4 Conclusion and Future Perspectives 54
References 55
5 Sorafenib 61
Jens Hasskarl
5.1 Introduction 61
5.2 Structure and Mechanism of Action 62
5.3 Clinical Data 64
5.3.1 Phase 1 64
5.3.2 Sorafenib in the Treatment of Renal Cell Cancer (RCC) 64
5.3.3 Sorafenib in the Treatment of Lung Cancer 66
5.3.4 Sorafenib in the Treatment of Hepatocellular Cancer (HCC) 66
5.3.5 Sorafenib in the Treatment of Breast Cancer 66
5.3.6 Sorafenib in the Treatment of Malignant Melanoma 66
5.3.7 Sorafenib in the Treatment of Prostate Cancer 67
Contents Vji
5.3.8 Sorafenib in the Treatment of Head and Neck Cancer 67
5.3.9 Sorafenib in the Treatment of Ovarian Cancer 67
5.3.10 Sorafenib in the Treatment of Brain Tumors 67
5.3.11 Sorafenib in the Treatment of Thyroid Cancer 67
5.3.12 Sorafenib in the Treatment of Hematologic Diseases 67
5.4 Conclusion and Future Perspectives 68
References 68
6 Sunitinib 71
Daniel Y. C. Heng and Christian Kollmannsberger
6.1 Introduction 71
6.2 Sunitinib 71
6.3 Renal Cell Carcinoma 72
6.3.1 Targets for Renal Cell Carcinoma 72
6.3.2 Phase II/III Studies in Metastatic RCC 74
6.4 Gastrointestinal Stromal Tumors 75
6.4.1 Targets for Gastrointestinal Stromal Tumors 75
6.4.2 GIST Clinical Trials 75
6.4.3 Side Effects 76
6.4.4 Drug Interactions 78
6.4.5 Activity in Other Tumor Sites and Ongoing Research 78
6.5 Conclusion 79
References 79
7 Dasatinib 83
Markus Lindauer and Andreas Hochhaus
7.1 Introduction 83
7.2 Structure and Mechanism of Action 85
7.2.1 Inhibition of ABL 86
7.2.2 Inhibition of SRC 87
7.2.3 Inhibition of c-KIT 87
7.2.4 Inhibition of Platelet-Derived Growth Factor Receptor
(PDGFR)-a and p Tyrosine Kinases 88
7.2.5 Inhibition of Ephrin Receptor Tyrosine Kinases 88
7.2.6 Additional Effects xx
7.3 Clinical Data 88
7.3.1 Pharmacokinetic Profile 88
7.3.2 Clinical Studies with Dasatinib in CML
and Other Diseases 89
7.3.3 CML and Phf ALL - Overview 89
7.3.4 Dasatinib and Other Diseases 95
7.3.5 Safety and Tolerability 96
7.4 Conclusion and Further Perspectives 98
References
viii Contents
8 Nilotinib 103
Alfonso Quintas-Cardama, Theo Daniel Kim, Vince Cataldo,
and Philipp le Coutre
8.1 Background 103
8.2 Preclinical and Pharmacokinetic Data 104
8.2.1 Pharmacological Design 104
8.2.2 Drug Targets 104
8.2.3 Preclinical Activity 104
8.2.4 Pharmacokinetics and Metabolism 105
8.3 Clinical Efficacy 105
8.3.1 Nilotinib Phase I Study 106
8.3.2 Nilotinib After Imatinib Failure 106
8.3.3 Nilotinib First-Line Therapy 108
8.3.4 Nilotinib After Dasatinib Failure 108
8.3.5 Toxicity 109
8.3.6 Resistance to Nilotinib 112
8.4 Outlook 113
8.5 Conclusion 114
References 114
9 Bosutinib 119
Gunhild Keller, Philippe Schafhausen, and Tim H. Briimmendorf
9.1 Chemical Structure 119
9.2 Mechanism of Action 119
9.2.1 SRC Kinase Inhibition 120
9.2.2 Abl and bcr-abl Inhibition 120
9.3 Bosutinib in Chronic Myeloid Leukaemia (CML) 121
9.3.1 Preclinical Data 121
9.3.2 Clinical Trials 121
9.4 Bosutinib in Solid Tumours 124
9.4.1 Preclinical Data 124
9.4.2 Clinical Trials 125
9.5 Conclusion and Future Directions 125
References 126
Part II Epigenetic Modifiers
10 Decitabine 131
Michael Daskalakis, Nadja Blagitko-Dorfs, and Bjorn Hackanson
10.1 Introduction 131
10.2 Structure and Mechanism of Action 132
10.3 Studies of Single-Agent Decitabine in MDS
and Acute Leukemias 133
10.4 Combination Treatment in AML, MDS, and Other Diseases 135
Contents ix
10.5 Decitabine as a Preparative Agent in Allogeneic Stem Cell
Transplantation 140
10.6 Immunomodulation with Decitabine 142
10.7 Decitabine Treatment in Other Diseases 143
10.7.1 Activity of Decitabine in Patients with Acute
Lymphoblastic Leukemia 143
10.7.2 Activity of Decitabine in Patients with Chronic
Myeloid Leukemia 144
10.7.3 Activity of Decitabine in Patients with Idiopathic
Myelofibrosis (IMF) 145
10.7.4 Clinical Effects of Decitabine in Severe p -Thalassemia
and Sickle Cell Disease 145
10.7.5 Efficacy of Decitabine in Patients with Solid Tumors 146
10.8 Conclusion and Future Perspectives 148
References 149
11 5-Azacytidine/Azacitidine 159
Antonia Miiller and Mareike Florek
11.1 Introduction: 5-Azacytidine - Novel or Almost Historic? 159
11.2 Agent 160
11.2.1 Chemical Structure 160
11.2.2 Mode of Action 160
11.3 Pharmacology 61
11.3.1 Route of Administration and Dosage 161
11.3.2 Bioavailability, Half-Life, Elimination, Drug-Drug
Interactions 162
11.3.3 Safety, Side Effects, and Contraindications 162
11.4 Clinical Use of 5-Azacytidine 64
11.4.1 Early Studies 164
11.4.2 5-Azacytidine in Myelodysplastic Syndromes (MDS) 164
11.4.3 New Therapeutic Approaches 66
11.5 Future Perspective, Experimental Studies, and Conclusion 166
References 6
Part HI Cell Cycle Inhibitors
12 Bortezomib 173
Hermann Einsele
12.1 Mode of Action 173
12.2 Antitumor Effects 175
12.3 Clinical Application of Proteasome Inhibitors 176
12.4 Bortezomib 177
12.5 Bortezomib-Based Combination Therapy
for Multiple Myeloma
x Contents
12.6 Treatment Options for Patients Eligible for Transplant 179
12.7 Next Generation Proteasome Inhibitors 179
References 180
13 Temsirolimus 189
Christian Stock, Massimo Zaccagnini, Michael Schulze, Dogu Teber,
and Jens J. Rassweiler
13.1 Introduction 189
13.2 Development 190
13.3 Structure and mechanism of action 190
13.4 Clinical Data 192
13.5 Safety and Efficacy 192
13.6 Side Effects 193
13.7 Conclusion and Future Perspectives 194
References 195
14 Danusertib (formerly PHA-739358) - A Novel Combined Pan-Aurora
Kinascs and Third Generation Bcr-Abl Tyrosine Kinase Inhibitor 199
Artur Gontarewicz and Tim H. Briimmendorf
14.1 Introduction 199
14.2 Structure, Localization, and Functions 200
14.3 Aurora Kinases and Cancer 201
14.4 Inhibitors 202
14.5 Danusertib (formerly PHA-739358) 204
14.6 Conclusion 208
References 209
15 BI_2536 - Targeting the Mitotic Kinase Polo-Like Kinase 1 (Plkl) 215
R. Wasch, J. Hasskarl, D. Schnerch, and M. Liibbert
15.1 Introduction 215
15.2 Structure and Mechanism of Action 217
15.3 Clinical Data 217
15.4 Conclusion and Future Perspectives 218
References 218
Part IV Other Novel Agents
16 Imetelstat (GRN163L) - Telomerase-Based Cancer Therapy 221
Alexander Roth, Calvin B. Harley, and Gabriela M. Baerlocher
16.1 Introduction 221
16.2 Telomerase-Based Approaches of Cancer Treatment 224
16.3 Telomerase Inhibition 224
16.4 Structure of Imetelstat and Mechanism of Action 224
Contents xi
16.5 Preclinical and Clinical Data of Imetelstat 225
16.6 Conclusion and Future Prospects 229
References 229
17 GDC-0449 - Targeting the Hedgehog Signaling Pathway 235
Christine Dierks
17.1 Introduction 235
17.2 Structure and Mechanism of Action 236
17.3 Clinical Data 236
17.4 Conclusion and Future Perspectives 237
References 237
|
| any_adam_object | 1 |
| author_GND | (DE-588)132250608 |
| building | Verbundindex |
| bvnumber | BV035862003 |
| callnumber-first | R - Medicine |
| callnumber-label | RC261 |
| callnumber-raw | RC261 |
| callnumber-search | RC261 |
| callnumber-sort | RC 3261 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | XI 7000 |
| ctrlnum | (OCoLC)495596327 (DE-599)BVBBV035862003 |
| dewey-full | 616.994061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994061 |
| dewey-search | 616.994061 |
| dewey-sort | 3616.994061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01956nam a2200505 cb4500</leader><controlfield tag="001">BV035862003</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20091217 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">091204s2010 gw ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783642012211</subfield><subfield code="9">978-3-642-01221-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783642012228</subfield><subfield code="9">978-3-642-01222-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)495596327</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV035862003</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-12</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC261</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994061</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 7000</subfield><subfield code="0">(DE-625)153024:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Small molecules in oncology</subfield><subfield code="c">Uwe M. Martens (ed.)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin [u.a.]</subfield><subfield code="b">Springer</subfield><subfield code="c">2010</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVI, 238 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Recent results in cancer research</subfield><subfield code="v">184</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic Agents</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic agents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Azacitidine</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Molecular aspects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Treatment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protein Kinase Inhibitors</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Kleines Molekül</subfield><subfield code="0">(DE-588)4164124-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Kleines Molekül</subfield><subfield code="0">(DE-588)4164124-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Martens, Uwe Marc</subfield><subfield code="d">1966-</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)132250608</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Recent results in cancer research</subfield><subfield code="v">184</subfield><subfield code="w">(DE-604)BV000000043</subfield><subfield code="9">184</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018719832&sequence=000004&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-018719832</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV035862003 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T22:06:23Z |
| institution | BVB |
| isbn | 9783642012211 9783642012228 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-018719832 |
| oclc_num | 495596327 |
| open_access_boolean | |
| owner | DE-29 DE-19 DE-BY-UBM DE-12 |
| owner_facet | DE-29 DE-19 DE-BY-UBM DE-12 |
| physical | XVI, 238 S. Ill., graph. Darst. |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | Springer |
| record_format | marc |
| series | Recent results in cancer research |
| series2 | Recent results in cancer research |
| spelling | Small molecules in oncology Uwe M. Martens (ed.) Berlin [u.a.] Springer 2010 XVI, 238 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Recent results in cancer research 184 Antineoplastic Agents therapeutic use Antineoplastic agents Azacitidine therapeutic use Cancer Molecular aspects Cancer Treatment Neoplasms drug therapy Protein Kinase Inhibitors therapeutic use Cytostatikum (DE-588)4068347-3 gnd rswk-swf Kleines Molekül (DE-588)4164124-3 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Cytostatikum (DE-588)4068347-3 s Kleines Molekül (DE-588)4164124-3 s DE-604 Martens, Uwe Marc 1966- Sonstige (DE-588)132250608 oth Recent results in cancer research 184 (DE-604)BV000000043 184 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018719832&sequence=000004&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Small molecules in oncology Recent results in cancer research Antineoplastic Agents therapeutic use Antineoplastic agents Azacitidine therapeutic use Cancer Molecular aspects Cancer Treatment Neoplasms drug therapy Protein Kinase Inhibitors therapeutic use Cytostatikum (DE-588)4068347-3 gnd Kleines Molekül (DE-588)4164124-3 gnd |
| subject_GND | (DE-588)4068347-3 (DE-588)4164124-3 (DE-588)4143413-4 |
| title | Small molecules in oncology |
| title_auth | Small molecules in oncology |
| title_exact_search | Small molecules in oncology |
| title_full | Small molecules in oncology Uwe M. Martens (ed.) |
| title_fullStr | Small molecules in oncology Uwe M. Martens (ed.) |
| title_full_unstemmed | Small molecules in oncology Uwe M. Martens (ed.) |
| title_short | Small molecules in oncology |
| title_sort | small molecules in oncology |
| topic | Antineoplastic Agents therapeutic use Antineoplastic agents Azacitidine therapeutic use Cancer Molecular aspects Cancer Treatment Neoplasms drug therapy Protein Kinase Inhibitors therapeutic use Cytostatikum (DE-588)4068347-3 gnd Kleines Molekül (DE-588)4164124-3 gnd |
| topic_facet | Antineoplastic Agents therapeutic use Antineoplastic agents Azacitidine therapeutic use Cancer Molecular aspects Cancer Treatment Neoplasms drug therapy Protein Kinase Inhibitors therapeutic use Cytostatikum Kleines Molekül Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018719832&sequence=000004&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000000043 |
| work_keys_str_mv | AT martensuwemarc smallmoleculesinoncology |